Emergent reshuffles its manufacturing brain trust as CEO sends mixed messages around Covid-19 vaccine debacle

Josh Sullivan

Weeks after Maryland-based Emergent BioSolutions bungled 15 million doses of J&J’s Covid-19 shot and was shut out of its own Baltimore facility, the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Emergent reshuffles its manufacturing brain trust as CEO sends mixed messages around Covid-19 vaccine debacle

Josh Sullivan

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

Novartis to cut 139 jobs in NJ as part of commercial refocus

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Emer­gent reshuf­fles its man­u­fac­tur­ing brain trust as CEO sends mixed mes­sages around Covid-19 vac­cine de­ba­cle

Josh Sullivan

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Emergent reshuffles its manufacturing brain trust as CEO sends mixed messages around Covid-19 vaccine debacle

Applied Therapeutics' rare disease drug gets a CRL

Novartis to cut 139 jobs in NJ as part of commercial refocus

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway